[go: up one dir, main page]

CA2649182C - Procedes et compositions portant sur des particules de phage de virus adenoassocie - Google Patents

Procedes et compositions portant sur des particules de phage de virus adenoassocie Download PDF

Info

Publication number
CA2649182C
CA2649182C CA2649182A CA2649182A CA2649182C CA 2649182 C CA2649182 C CA 2649182C CA 2649182 A CA2649182 A CA 2649182A CA 2649182 A CA2649182 A CA 2649182A CA 2649182 C CA2649182 C CA 2649182C
Authority
CA
Canada
Prior art keywords
aavp
fluoro
uracil
beta
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2649182A
Other languages
English (en)
Other versions
CA2649182A1 (fr
Inventor
Renata Pasqualini
Wadih Arap
Juri Gelovani
Frank C. Marini, Iii
Amin Hajitou
Mian Alauddin
Martin Trepel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA2649182A1 publication Critical patent/CA2649182A1/fr
Application granted granted Critical
Publication of CA2649182C publication Critical patent/CA2649182C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Oncology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)

Abstract

Les modes de réalisation de la présente invention concernent généralement des compositions et des procédés permettant d'administrer un ou plusieurs transgènes dans une cellule cible, telle une cellule tumorale, de façon spécifique au site afin de parvenir à une expression accrue et de créer des compositions se révélant utiles dans de telles applications. Dans certains aspects, l'expression d'un acide nucléique thérapeutique peut être évaluée avant l'administration d'un traitement ou la procédure de diagnostic relative à un sujet.
CA2649182A 2006-04-07 2007-04-09 Procedes et compositions portant sur des particules de phage de virus adenoassocie Active CA2649182C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74449206P 2006-04-07 2006-04-07
US60/744,492 2006-04-07
PCT/US2007/066265 WO2007118245A2 (fr) 2006-04-07 2007-04-09 Procedes et compositions portant sur des particules de phage de virus adenoassocie

Publications (2)

Publication Number Publication Date
CA2649182A1 CA2649182A1 (fr) 2007-10-18
CA2649182C true CA2649182C (fr) 2018-01-02

Family

ID=38581871

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2649182A Active CA2649182C (fr) 2006-04-07 2007-04-09 Procedes et compositions portant sur des particules de phage de virus adenoassocie

Country Status (9)

Country Link
US (4) US20070274908A1 (fr)
EP (1) EP2009990B1 (fr)
JP (1) JP5479087B2 (fr)
CN (1) CN101460055A (fr)
AU (1) AU2007234698B2 (fr)
BR (1) BRPI0710671B8 (fr)
CA (1) CA2649182C (fr)
DK (1) DK2009990T3 (fr)
WO (1) WO2007118245A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101022401B1 (ko) * 2005-09-29 2011-03-15 아주대학교산학협력단 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물
EP2128259A1 (fr) * 2008-05-27 2009-12-02 Koninklijke Philips Electronics N.V. Administration de thérapie et surveillance utilisant un gène de protéine de fusion de rapporteur-intérêt et imagerie optique
FI3581650T3 (fi) * 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
WO2011140365A1 (fr) * 2010-05-05 2011-11-10 Auburn University Particules cibles comprenant des protéines de fusion de phage d'environnement et un acide nucléique hétérologue
EP2444101A1 (fr) * 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Ciblage sélectif de l'interaction CD40L/Mac-1 par des inhibiteurs de petits peptides et son utilisation pour la traitement de l'inflammation et de l'athérogénèse
WO2012058522A2 (fr) * 2010-10-28 2012-05-03 Virginia Commonwealth University Imagerie du cancer au moyen d'une thérapie : la théranostique
US20140227182A1 (en) * 2013-02-19 2014-08-14 The Johns Hopkins University Cancer imaging with therapy: theranostics
GB201121069D0 (en) * 2011-12-07 2012-01-18 Isis Innovation Delivery system
CN102535760A (zh) * 2011-12-22 2012-07-04 彭长大 拼装型平屋面绿化种菜隔热装置
US10508143B1 (en) 2015-10-30 2019-12-17 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
MX2018005348A (es) 2015-10-30 2018-08-14 Aleta Biotherapeutics Inc Composiciones y metodos para transduccion de tumores.
GB201519303D0 (en) * 2015-11-02 2015-12-16 Imp Innovations Ltd Phagemid vector
KR20190141655A (ko) * 2017-02-22 2019-12-24 알레타 바이오쎄라퓨틱스, 인크. 종양 형질도입용 조성물 및 방법
GB201706451D0 (en) 2017-04-24 2017-06-07 Imp Innovations Ltd Cancer treatment
JP2021508443A (ja) 2017-12-15 2021-03-11 アレタ・バイオセラピューティクス・インコーポレイテッドＡｌｅｔａ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Ｃｄ１９変異体
US12419970B2 (en) 2018-04-18 2025-09-23 The Trustees Of Columbia University In The City Of New York Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN109517807A (zh) * 2018-11-20 2019-03-26 暨南大学 一种心脏血管靶向的噬菌体载体及其用途
KR20210104828A (ko) 2018-12-19 2021-08-25 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 리소좀 표적화를 위한 이작용성 분자 및 관련된 조성물 및 방법
US11155835B2 (en) * 2019-08-19 2021-10-26 The Catholic University Of America Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
WO2023288033A1 (fr) 2021-07-14 2023-01-19 Lycia Therapeutics, Inc. Composés et conjugués de liaison au récepteur de surface cellulaire asgpr
CN116790521A (zh) * 2023-06-20 2023-09-22 扬州大学 一种可识别肿瘤表面的cea蛋白与表达egfp蛋白的重组噬菌体及其构建与应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5246924A (en) * 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
US5432260A (en) * 1991-05-03 1995-07-11 Washington University High affinity mannose receptor ligands
BR9306393A (pt) 1992-05-19 1998-09-15 Graham Edmund Kelly Suplemento natural e processo para melhorar a saúde de um ser humano
US5643756A (en) * 1992-08-28 1997-07-01 The Public Health Research Institute Of The City Of New York, Inc. Fusion glycoproteins
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US6068829A (en) * 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
US5871727A (en) * 1995-12-08 1999-02-16 Uab Research Foundation Targeted adenovirus vectors
JP4203835B2 (ja) 1996-08-19 2009-01-07 アメリカ合衆国 全身への送達を増加させる新規のリポソーム複合体
US6576239B1 (en) * 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US6723512B2 (en) * 1997-08-29 2004-04-20 Selective Genetics Inc. Methods using genetic package display for detecting and identifying protein-protein interactions that facilitate internalization and transgene expression and cells or tissues competent for the same and methods for evolving gene delivery vectors
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6232287B1 (en) * 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US20010046498A1 (en) * 2000-01-21 2001-11-29 Ruoslahti Erkki I. Chimeric prostate-homing peptides with pro-apoptotic activity
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US7420030B2 (en) * 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) * 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
TWI247609B (en) * 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
US20020122806A1 (en) * 2001-03-05 2002-09-05 Chinnaiyan Arul M. Compositions and methods for in situ and in vivo imaging of cells and tissues
DE60207733T2 (de) * 2001-07-30 2006-06-29 Smithkline Beecham Corp. Abbildung von transgenen markern
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
WO2003033723A2 (fr) * 2001-10-18 2003-04-24 Aventis Pharmaceuticals Inc. Vecteurs d'expression de transgenes multiples
WO2003066883A2 (fr) * 2002-02-08 2003-08-14 The Regents Of The University Of California Systeme d'amplification de transcription pour imagerie moleculaire
EP1546714A4 (fr) * 2002-08-30 2007-12-05 Univ Texas Compositions et procedes d'utilisation de peptides de ciblage con us pour le diagnostic et le traitement du cancer humain
US20040219098A1 (en) 2003-05-02 2004-11-04 Jasbir Sandhu Methods for the treatment of tumors
US20050187161A1 (en) * 2003-09-12 2005-08-25 Board Of Regents, The University Of Texas System Biopanning as an approach to study the pathogenesis of and produce novel treatment modalities for invasive Aspergillosis
CN102174574B (zh) * 2003-09-30 2016-08-03 宾夕法尼亚大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
US20050191294A1 (en) * 2003-12-31 2005-09-01 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
CN101432305B (zh) 2004-06-07 2014-07-30 雷文生物技术公司 运铁蛋白受体抗体

Also Published As

Publication number Publication date
BRPI0710671B8 (pt) 2021-05-25
US20120178903A1 (en) 2012-07-12
US8470528B2 (en) 2013-06-25
CA2649182A1 (fr) 2007-10-18
US20100254896A1 (en) 2010-10-07
DK2009990T3 (en) 2017-01-09
BRPI0710671B1 (pt) 2020-08-11
US20180256740A1 (en) 2018-09-13
WO2007118245A3 (fr) 2008-11-13
BRPI0710671A2 (pt) 2011-08-16
AU2007234698A1 (en) 2007-10-18
JP5479087B2 (ja) 2014-04-23
WO2007118245A8 (fr) 2008-10-02
AU2007234698B2 (en) 2013-08-01
JP2009534314A (ja) 2009-09-24
EP2009990A2 (fr) 2009-01-07
EP2009990B1 (fr) 2016-09-21
US20070274908A1 (en) 2007-11-29
EP2009990A4 (fr) 2010-12-01
CN101460055A (zh) 2009-06-17
US9827327B2 (en) 2017-11-28
WO2007118245A2 (fr) 2007-10-18

Similar Documents

Publication Publication Date Title
CA2649182C (fr) Procedes et compositions portant sur des particules de phage de virus adenoassocie
EP3610023B1 (fr) Vecteurs viraux adéno-associés polyploïdes et leurs procédés de fabrication et d'utilisation
CN114127089A (zh) 重组腺相关病毒及其用途
EP0963434A1 (fr) Procedes permettant l'optimisation de la therapie genique grace a un rearrangement et une selection recursifs de sequences
CA2266423A1 (fr) Procedes permettant l'optimisation d'une therapie genique grace a un rearrangement et une selection recursifs de sequences
EP2997148B1 (fr) Bactériophage
Mount et al. Cell targeted phagemid rescued by preselected landscape phage
CA3167290A1 (fr) Procedes et compositions pour l'administration d'agents d'immunotherapie a travers la barriere hemato-encephalique pour traiter le cancer du cerveau
Boulikas Status of gene therapy in 1997: molecular mechanisms, disease targets, and clinical applications
CA2479759A1 (fr) Complexes de vecteur adenoviral-protamine et procedes d'utilisation
EP0959135A1 (fr) Présentation de protéines virales et délivrance ciblée au récepteur cellulaire
US20070264191A1 (en) Materials and Methods Relating to the Treatment of Glioblastomas
WO2009081154A1 (fr) Administration ciblée de macromolécules
Brun Design of Caspase and MMP-Activatable Adeno-Associated Virus Vectors and Their In Vivo Application
EP0972841A1 (fr) Présentation de protéines virales comme ligands de récepteur cellulaire de surface
Alméciga-Díaz et al. Gene delivery systems: tailoring vectors to reach specific tissues
Guenther Expanding the Toolkit of Protease Activatable Viruses to Improve Their Versatility and Modularity
Yata Bacteriophage: From Bacteria to Targeted Gene Delivery to Mammalian Cells
Pützer et al. Vector Technology and Cell Targeting: Peptide-Tagged Adenoviral Vectors as a Powerful Tool for Cell Specific Targeting
Somiari Gene Therapy: Methods and Application
Kritz Peptides from phage display libraries for targeted gene delivery via the p75NTR neurotrophic receptor
Nicol The development of genetically-targeted adenoviral vectors for in vivo delivery to the heart
HK40021301A (en) Polyploid adeno-associated virus vectors and methods of making and using the same

Legal Events

Date Code Title Description
EEER Examination request